Clinical Trial Update: A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors [Phase 2]

View source ↗

Summary

Phase 2 trial assessing relatlimab in combination with nivolumab in advanced hepatocellular carcinoma patients who have not received prior immuno-oncology thera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Relatlimab (relatlimab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatocellular Carcinoma, Hepatoma | Phase 2 | Status: COMPLETED | Results posted: 2024-10-08